Breast Cancer Drug Futures

Date: October 1, 2010
Price:
US$ 2,615.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BA82292AE57EN
Leaflet:

Download PDF Leaflet

Breast Cancer Drug Futures
AN EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING FORMATS TO MEET EVERY INFORMATION NEED

Espicom's Breast Cancer Drug Futures includes formats to meet differing information requirement of customers. For constant vigilance and up-to-date coverage of lung cancer drug development users can access the 24/7 daily updated web service. For strategic periodic reviews we also provide quarterly-updated reports of all drugs in a convenient pdf document. All for one cost-effective annual price of £1,495/US$2,615/€1,865

24/7 web access
Quarterly updated pdf reports
Single cost-effective price
All updates including any new drugs added during your license period
Related news
Espicom’s research methodology for forecasting and including an explanation of the competitor ratio analysis scoring system.

Globally, breast cancer is the second most common cancer after lung cancer....
....and the most common cancer for women. It is the second most common cause of death from cancer in women after lung cancer.
The breast cancer market is a steadily growing market due to effective treatments which have decreased mortality and resulted in a longer duration of therapy. The five-year survival rates for women with breast cancer have increased from under 70% 50 years ago to around 90% now.

Approximately 47% of breast cancer sales were derived from the US, with 41% Europe and 12% in Japan. Over the next six years Espicom forecasts that novel therapies including targeted monoclonal antibodies and small-molecule inhibitors, will increasingly be used in combination with chemotherapy and hormonal therapy.

NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER

This all new web service from Espicom, Breast Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.

WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN...
  • Track the drug’s progress and stay in-touch with developments
  • Understand the drug’s novelty and mode of action
  • Evaluate the strength of the company developing/producing the drug
  • Review opportunities and challenges with Espicom’s unique 5-point competitive assessment
  • Know the launch timeframe for new products or indications
  • Be aware of promising mid-stage development candidates
  • Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates
  • Review significant clinical trial results
STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS

For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include…
  • Novelty/rationale for mechanism of action
  • Current status
  • Proof of concept/clinical data
  • Development risks
  • Company expertise
  • Competition within the market-place
  • Sales forecast (for key late-stage and launched products)
  • Competitor ratio analysis score
  • Clinical trial results
OVER 65 CURRENT PROJECTS COVERED:
Because this service is continually updated, products will be added, deleted or enhanced in response to ongoing developments throughout the course of your licence. From time-to-time drug profiles may be removed from the service for essential updating.

Approved
  • Anastrozole
  • Bevacizumab
  • BIIB021
  • Capecitabine
  • Docetaxel
  • Doxorubicin
  • Fulvestrant
  • Gemcitabine
  • Goserelin
  • Ixabepilone
  • Lapatinib
  • Letrozole
  • Paclitaxel
  • Pazopanib
  • Saracatinib
  • Tamoxifen
  • Tegafur+gimeracil+oteracil
  • Tegafur+uracil
Phase I/II
  • AUY922
  • BIIB021
  • IMP321
  • MVA-BN-HER2
  • Tivozanib
Phase III
  • Erbulin
  • Everolimus
  • Pertuzumab
  • Ramucirumab
  • Trabectedin
  • Vadimezan
Phase I
  • Adecatumumab
  • Brivanib
  • PTC299
Phase II/III
  • Pazopanib
Withdrawn
  • Saracatinib
  • Sagopilone
  • Sunitinib malate
Phase II
  • AE37
  • Axitinib
  • Bavituximab
  • Cixutumumab
  • E75 GM-CSF adjuvant vaccine
  • Figitumumab
  • Gimatecan
  • Linifanib
  • Motesanib diphosphate
  • NOV-002
  • Olaparib
  • Pemetrexed disodium
  • Retaspimycin
  • Sorafenib
  • SU14813
  • TSU-68
  • YM155
CLEAR, CONCISE, AND ORIGINAL ANALYSIS GIVES YOU KEY PRODUCT INSIGHTS

Espicom's Cancer Drug Futures incorporate the latest analysis from our in-house team of life scientists and statisticians across a range of cancer areas. Their research builds upon Espicom's established knowledge base of up-to-date intelligence on thousands of pharmaceutical manufacturers and research companies, backed up by a fifteen years’ of archive material.

Taking all aspects of the market into account, from clinical trials, deals and alliances to company financial performance and drug sales, the analysis and forecasting that contributes to Espicom's Cancer Drug Futures is standardised across each individual launched product or drug candidate and is founded upon a diligent and thorough research process.

With Espicom’s Cancer Drug Futures you can easily evaluate the prospects of the drugs of interest to you and discover its progress in each indication. Each report provides individual and highly-detailed analysis of the drug, looking at the key factors affecting its future performance in the marketplace.

BUILD YOUR OWN DRUG FUTURES LIBRARY WITH 4D RESEARCH!

4D Research is Espicom’s tailored information service. Using 4D Research, customers can build their own Futures library of individual drugs of interest. Indeed, the service can include any of Espicom’s leading information services. Attractive discounts are available to buyers of multiple Futures and our cost-effective distribution license means these key data can be shared with colleagues.

For further information on the products covered, discounts, distribution or a demonstration, please click on the link for Mark Hamson.

CANCER SECTORS COVERED IN THE DRUG FUTURE SERVICE
  • Breast
  • Lung
  • Colorectal
  • Renal Cell Carcinoma
  • Prostate
  • Blood (coming soon)
OVERVIEW

ADECATUMUMAB


Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Clinical Trial Results

GDC-0941

Mode of Action
Current Status
Company Expertise

BRIVANIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

PTC299

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise

AUY922

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

BIIB021

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

DASATINIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results
Chronic Myelogenous Leukaemia

IMP321

Mode of Action
Current Status
Proof of Concept/Clinical Data
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

ISPINESIB

Mode of Action
Current Status
Clinical Trial Results

MVA-BN-HER2

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

TIVOZANIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

AE37

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

AXITINIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

BAVITUXIMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

BIBW 2992

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

BOSUTINIB

Mode of Action
Current Status
Clinical Trial Results

CIXUTUMUMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

E75 GM-CSF ADJUVANT VACCINE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition Within the Market-place
Competitor Ratio Analysis
Forecast

FIGITUMUMAB

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

GIMATECAN

Mode of Action
Proof of Concept/Clinical Data

LINIFANIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

MOTESANIB DIPHOSPHATE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

NOV-002

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

OLAPARIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

RETASPIMYCIN

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

RETASPIMYCIN

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

SORAFENIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Competitor Ratio Analysis
Forecast

SU14813

Mode of Action
Current Status

TAS-108

Mode of Action
Current Status

TSU-68

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

VANDETANIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition Within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

YM155

Current Status
Proof of Concept/Clinical Data

CANFOSFAMIDE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

PAZOPANIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Competitor Ratio Analysis
Forecast
Clinical Trial Results

BSI-201

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

ERBULIN

Clinical Trial Results

EVEROLIMUS

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

NERATINIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Clinical Trial Results

PERTUZUMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

RAMUCIRUMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

TRABECTIDIN

Mode of Action
Current Status
Further Development

VADIMEZAN

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition Within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

ANASTROZOLE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition Within the Market-place
Data Exclusivity
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast
Clinical Trial Results

BEVACIZUMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

CAPECITABINE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Patent Expiry
Competitor Ratio Analysis
Forecast
Clinical Trial Results

DOCETAXEL

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

DOXIFLURIDINE

Mode of Action
Current Status

DOXORUBICIN

Clinical Trial Results

EXEMESTANE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Competitor Ratio Analysis
Forecast

FULVESTRANT

Mode of Action
Sales
Current Status
Proof of concept/clinical data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

GEMCITABINE

Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast
Clinical Trial Results
Metastatic Breast Cancer
Pancreatic Cancer

GOSERELIN

Mode of Action
Sales
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition Within the Market-place
Competitor Ratio Analysis
Forecast

IXABEPILONE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

LAPATINIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Competitor Ratio Analysis
Forecast
Clinical Trial Results

LETROZOLE

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast
Clinical Trial Results

PACLITAXEL ALBUMIN-BOUND PARTICLES

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition Within the Market-place
Data Exclusivity
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast
Clinical Trial Results

PACLITAXEL

RALOXIFENE


Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast
Clinical Trial Results

TAMOXIFEN

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Generic Competition
Competitor Ratio Analysis
Forecast

TOREMIFENE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

TRASTUZUMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Patent Expiry
Competitor Ratio Analysis
Forecast
Clinical Trial Results

ABT-751

Mode of Action
Current Status

ARZOXIFENE

Mode of Action
Current Status
Proof of Concept/Clinical Data

ENZASTAURIN

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

SAGOPILONE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

PD-325901

Mode of Action
Current Status
Proof of Concept/Clinical Data

SARACATINIB

Mode of Action
Current Status

SUNITINIB MALATE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast
Clinical Trial Results

TANESPIMYCIN

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

METHODOLOGY
Breast Cancer Drugs: World Market Prospects 2010-2025 US$ 2,325.00 Jun, 2010 · 135 pages
Global Breast Cancer Drugs Market 2011-2015 US$ 1,200.00 Jul, 2012 · 36 pages
Lung Cancer Drug Futures US$ 2,615.00 Oct, 2010
Colorectal Cancer Drug Futures US$ 2,615.00 Oct, 2010

Ask Your Question

Breast Cancer Drug Futures
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: